Trump’s ‘Go Wild On Health’ Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform

President-elect Donald Trump has announced that Robert F. Kennedy Jr. (RFK Jr.) will serve as the Secretary of Health and Human Services (HHS). Trump described Kennedy’s mission as one to address the “industrial food complex” and pharmaceutical companies, which he accused of spreading “misinformation and disinformation.”

In his announcement, Trump emphasized that Kennedy’s leadership would “restore these agencies to the traditions of gold standard scientific research and beacons of transparency to end the chronic disease epidemic.” He also noted that the safety and health of Americans would remain a central focus of the new administration.

Earlier remarks by Trump indicated that Kennedy would be given significant freedom in his role, with the president-elect stating that he would allow Kennedy to “go wild on health” to address systemic issues in the country’s healthcare system. While the specific implications of this statement remain unclear, it reflects Trump’s confidence in Kennedy’s ability to tackle what he views are broad public health challenges.

Polarizing Appointment With Major Implications

Kennedy’s appointment has drawn attention due to his well-documented skepticism about vaccine safety, including his past promotion of debunked theories linking vaccines to autism, claims widely rejected by the scientific community. This history raises questions about how RFK’s leadership will influence key public health initiatives.

Despite this background, Kennedy’s policy positions on cannabis and psychedelics suggest he could drive significant reforms in these areas. His advocacy for these substances has gained traction as public opinion shifts and bipartisan support grows for drug policy reform.

Kennedy’s Cannabis Policy Vision

As HHS Secretary, Kennedy’s approach to cannabis will likely be closely scrutinized. He has consistently advocated for federal decriminalization, envisioning a framework where states can regulate cannabis while the federal government collects tax revenue to fund rehabilitation centers. These centers, which RFK has proposed establishing in rural areas, would emphasize holistic recovery practices, such as gardening and forestry.

Kennedy’s broader public health goals align with this vision. He has pushed for reducing barriers to entry for cannabis businesses while addressing addiction and recovery challenges nationwide. A significant element of his policy is enabling safe banking for cannabis businesses. He has called for reforms to end the industry’s reliance on cash transactions, which pose security risks and limit financial access.

Psychedelics: A Personal And Policy Frontier

Kennedy’s advocacy for psychedelics stems from both personal experiences and the growing body of research on their potential mental health benefits. He has shared how his son’s use of ayahuasca helped him process grief, an experience that informed Kennedy’s cautious but supportive stance on psychedelics.

“My inclination would be to make them available, at least in therapeutic settings and maybe more generally, but in ways that would discourage corporate control and exploitation,” Kennedy said in an interview with Genius Network in 2023. His perspective suggests a focus on accessibility while resisting the commercialization of these substances, aiming to prioritize therapeutic applications.

What’s Next For Reform?

Kennedy’s confirmation as HHS Secretary has sparked discussion about how his views will shape drug policy in the U.S. His positions on cannabis decriminalization, safe banking reforms and therapeutic uses of psychedelics align with increasing public and political support for change. However, his history of promoting discredited vaccine theories and his polarizing reputation could complicate efforts to build consensus within the administration and among public health stakeholders.

While the specifics of Kennedy’s role are still emerging, his appointment signals a potential pivot in federal approaches to cannabis and psychedelics. Industry stakeholders, from advocates to investors, will be watching closely to see whether his leadership results in meaningful reform.

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: Shutterstock